Lunit, a leader in AI-driven cancer diagnostic and therapeutic solutions, announced on Monday its strategic partnership with AstraZeneca to advance digital pathology solutions utilizing artificial intelligence. The focus of this collaboration is the Lunit SCOPE Genotype Predictor, an innovative AI tool designed to assess H&E slide images to forecast the probability of tumors containing NSCLC driver mutations, including Epidermal Growth Factor Receptor (EGFR) mutations.
Kristina Rodnikova, who spearheads Global Oncology Diagnostics within AstraZeneca's Oncology Business Unit, remarked, "Our partnership with Lunit reaffirms our dedication to enhancing precision medicine in oncology. Such tools will play a crucial role in addressing existing gaps by refining diagnostic processes for NSCLC patients, ultimately leading to better healthcare outcomes."